Abstract
The field of immuno-oncology (IO) is rapidly expanding, generating enormous interest on the part of drug developers and giving new hope to patients and physicians. Attempts to harness the immune system to fight cancer date back to the 19th century; however, it is only in recent years that immunotherapies have entered mainstream oncology and have shown promise across a broad range of tumor types. New therapeutic combinations are emerging, with companies pairing two immunotherapies, an immunotherapy and a molecularly targeted therapy, or an immunotherapy plus traditional chemotherapy in order to more effectively fight cancer. Some immunotherapies are also pairing with companion diagnostics in order to maximize efficacy in patient populations. All of these developments come with their own unique challenges that drug developers will need to confront. This Perspective article reviews developments in the IO field and highlights key challenges in successfully commercializing an IO therapy.
Keywords: Commercialization, companion diagnostics, immuno-oncology, oncology, precision medicine.
Current Pharmacogenomics and Personalized Medicine
Title:IO Nation: The Rise of Immuno-Oncology
Volume: 12 Issue: 3
Author(s): Scott Palmer, Georgiana L. Kuhlmann and Kristin Pothier
Affiliation:
Keywords: Commercialization, companion diagnostics, immuno-oncology, oncology, precision medicine.
Abstract: The field of immuno-oncology (IO) is rapidly expanding, generating enormous interest on the part of drug developers and giving new hope to patients and physicians. Attempts to harness the immune system to fight cancer date back to the 19th century; however, it is only in recent years that immunotherapies have entered mainstream oncology and have shown promise across a broad range of tumor types. New therapeutic combinations are emerging, with companies pairing two immunotherapies, an immunotherapy and a molecularly targeted therapy, or an immunotherapy plus traditional chemotherapy in order to more effectively fight cancer. Some immunotherapies are also pairing with companion diagnostics in order to maximize efficacy in patient populations. All of these developments come with their own unique challenges that drug developers will need to confront. This Perspective article reviews developments in the IO field and highlights key challenges in successfully commercializing an IO therapy.
Export Options
About this article
Cite this article as:
Palmer Scott, Kuhlmann L. Georgiana and Pothier Kristin, IO Nation: The Rise of Immuno-Oncology, Current Pharmacogenomics and Personalized Medicine 2014; 12 (3) . https://dx.doi.org/10.2174/1875692113666150115222451
DOI https://dx.doi.org/10.2174/1875692113666150115222451 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
RNA Binding Protein/RNA Element Interactions and the Control of Translation
Current Protein & Peptide Science Genetic and Pharmacological Modulation of Dendritic Cell-T Cell Interactions as a Therapeutic Strategy for Systemic Lupus Erythematosus
Current Gene Therapy The Polyhedric Abl Kinases and their Pharmacologic Inhibitors
Current Enzyme Inhibition Nanoemulsion Strategy for Ursolic and Oleanic Acids Isolates from Plumeria Obtusa Improves Antioxidant and Cytotoxic Activity in Melanoma Cells
Anti-Cancer Agents in Medicinal Chemistry Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry Antigenic Differences Between Normal and Malignant Cells as a Basis for Treatment of Intracerebral Neoplasms Using a DNA-Based Vaccine
Current Genomics Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter
Current Drug Metabolism Relations between GPR4 Expression, Microvascular Density (MVD) and Clinical Pathological Characteristics of Patients with Epithelial Ovarian Carcinoma (EOC)
Current Pharmaceutical Design Targeting Glioblastoma: The Current State of Different Therapeutic Approaches
Current Neuropharmacology Synthesis, DNA Binding Ability and Anticancer Activity of 2-heteroaryl Substituted Benzimidazoles Linked Pyrrolo[2,1-c][1,4]benzodiazepine Conjugates
Medicinal Chemistry Use of Cell Lines in the Investigation of Pharmacogenetic Loci
Current Pharmaceutical Design The Relation Between Stereochemistry and Biological Activity of Platinum(II) Complexes Chelated with Chiral Diamine Ligands: An Intricate Problem
Current Pharmaceutical Design Exploring siRNA Umpired Nanogels: A Tale of Barrier Combating Carrier
Current Pharmaceutical Design Ghrelin and Energy Balance: Focus on Current Controversies
Current Drug Targets When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Current Pharmaceutical Design Imaging in Melanoma Management: What's New Under the Sun?
Current Radiopharmaceuticals Peptide Vaccines for Cancer Therapy
Recent Patents on Inflammation & Allergy Drug Discovery Current Pharmacological Approaches to Prevent and Treat Post- Menopausal Osteoporosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors
Current Drug Delivery Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design